USPTO Examiner CANELLA KAREN A - Art Unit 1643

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18821737IMMUNOCONJUGATES AND METHODSAugust 2024December 2024Allow410YesNo
18821730IMMUNOCONJUGATES AND METHODSAugust 2024December 2024Allow410YesNo
18821707IMMUNOCONJUGATES AND METHODSAugust 2024December 2024Allow410YesNo
18821718IMMUNOCONJUGATES AND METHODSAugust 2024December 2024Allow410YesNo
18654735POLYOXAZOLINE-DRUG CONJUGATES WITH NOVEL PHARMACOKINETIC PROPERTIESMay 2024April 2025Allow1120YesNo
18654902POLYOXAZOLINE-DRUG CONJUGATES WITH NOVEL PHARMACOKINETIC PROPERTIESMay 2024April 2025Allow1120YesNo
18511818CEACAM5 ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOFNovember 2023September 2024Abandon1010NoNo
18559201COMPOSITIONS AND METHODS RELATED TO TUMOR ACTIVATED ANTIBODIES TARGETING EGFR AND EFFECTOR CELL ANTIGENSNovember 2023August 2024Allow910YesNo
18494007HER-2 TARGETED BISPECIFIC COMPOSITIONS AND METHODS FOR MAKING AND USING THE SAMEOctober 2023December 2024Allow1320NoNo
18479317IMMUNOCONJUGATES AND METHODSOctober 2023August 2024Allow1120NoNo
18349337ANTI-ROR1 ANTIBODY CONJUGATES, COMPOSITIONS COMPRISING ANTI ROR1 ANTIBODY CONJUGATES, AND METHODS OF MAKING AND USING ANTI-ROR1 ANTIBODY CONJUGATESJuly 2023September 2024Allow1421NoNo
18254882ANTIBODY-DRUG CONJUGATE, AND INTERMEDIATE THEREOF, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOFMay 2023October 2024Allow1730NoNo
18318384COVALENTLY-MODIFIED STEROID ACID-PEPTIDES HAVING ENHANCED STABILITY AND/OR BIOLOGICAL ACTIVITYMay 2023October 2024Allow1710NoNo
18169174DENDRITIC CELL TUMOR VACCINE AND USES THEREOFFebruary 2023June 2024Allow1640YesNo
18101285GLYCOME FACTORS DRIVING MELANOMA PROGRESSIONJanuary 2023November 2023Allow920NoNo
18062996ERIBULIN-BASED ANTIBODY-DRUG CONJUGATES AND METHODS OF USEDecember 2022January 2025Abandon2630NoNo
18056080ANTI-PSMA CONJUGATESNovember 2022May 2024Abandon1720NoNo
17936346IMMUNOCONJUGATES AND METHODSSeptember 2022August 2023Allow1120NoNo
17823494COMPOSITIONS AND METHODS FOR DELIVERY OF NUCLEIC ACIDS TO CELLSAugust 2022July 2023Allow1010NoNo
17823492COMPOSITIONS AND METHODS FOR DELIVERY OF NUCLEIC ACIDS TO CELLSAugust 2022September 2023Allow1320YesNo
17851340IMMUNOCONJUGATES TARGETING CD46 AND METHODS OF USE THEREOFJune 2022August 2024Allow2650NoNo
17836684PDGF MUTANTS AND METHODS OF USE THEREOFJune 2022February 2025Allow3340NoNo
17831085TREATMENT OF CANCER IN PATIENTS WITH SOLUBLE FR-ALPHAJune 2022December 2023Abandon1910NoNo
17663758COMPOSITIONS AND METHODS FOR TREATING EGFR POSITIVE CANCERSMay 2022November 2022Allow610NoNo
17736896Methods for Manipulating Phagocytosis Mediated by CD47May 2022July 2023Abandon1520NoNo
17754915POLYMERIC DRUG DELIVERY CONJUGATES AND METHODS OF MAKING AND USING THEREOFApril 2022April 2025Allow3660YesNo
17714295EXOSOME-BASED CANCER ASSAYSApril 2022December 2023Allow2041YesNo
17679213Low dose antibody-based methods for treating hematologic malignanciesFebruary 2022May 2025Allow3910NoNo
17631200SOLUBLE PROGRAMMED CELL DEATH PROTEIN-1 AS A BIOMARKER IN CANCER PATIENTSJanuary 2022August 2023Abandon1810NoNo
17560006BISPECIFIC ANTIBODY AGAINST CD3 AND CD20 IN COMBINATION THERAPY FOR TREATING DIFFUSE LARGE B-CELL LYMPHOMADecember 2021June 2022Allow610NoNo
17558404BISPECIFIC ANTIBODY AGAINST CD3 AND CD20 IN COMBINATION THERAPY FOR TREATING FOLLICULAR LYMPHOMADecember 2021June 2022Allow610NoNo
17552137METHODS FOR IDENTIFYING BETA-GLUCAN BINDING TO IMMUNE CELLSDecember 2021April 2025Allow4021NoNo
17519183Anti-CD25 Antibody-Maytansine Conjugates and Methods of Use ThereofNovember 2021August 2023Allow2120YesNo
17599309FUNCTIONALIZED POLY-ADP-RIBOSE POLYMERS FOR DRUG DELIVERYSeptember 2021September 2022Allow1120NoNo
17483588MULTISPECIFIC ANTIGEN-BINDING MOLECULES AND USES THEREOFSeptember 2021January 2025Allow4010NoNo
17476683Humanised Anti Kallikrein-2 AntibodySeptember 2021April 2025Allow4320NoNo
17439498Immunoconjugates Targeting CEASeptember 2021April 2025Abandon4310NoNo
17437617Immunoconjugates Targeting PD-L1September 2021April 2025Abandon4310NoNo
17434112COMPOUNDS USEFUL AS ADJUVANTSAugust 2021June 2025Abandon4610NoNo
17372354ANTI-SEZ6 ANTIBODY DRUG CONJUGATES AND METHODS OF USEJuly 2021March 2025Abandon4410NoNo
17351341NOVEL PEPTIDES AND COMBINATION OF PEPTIDES AND SCAFFOLDS THEREOF FOR USE IN IMMUNOTHERAPY AGAINST COLORECTAL CARCINOMA (CRC) AND OTHER CANCERSJune 2021August 2024Allow3810NoNo
17345457NOVEL PEPTIDES AND COMBINATION OF PEPTIDES AND SCAFFOLDS THEREOF FOR USE IN IMMUNOTHERAPY AGAINST COLORECTAL CARCINOMA (CRC) AND OTHER CANCERSJune 2021July 2024Allow3820YesNo
17339157PEPTIDES, COMBINATION OF PEPTIDES, AND CELL BASED MEDICAMENTS FOR USE IN IMMUNOTHERAPY AGAINST URINARY BLADDER CANCER AND OTHER CANCERSJune 2021April 2024Allow3510YesNo
17333945PEPTIDES, COMBINATION OF PEPTIDES, AND CELL BASED MEDICAMENTS FOR USE IN IMMUNOTHERAPY AGAINST URINARY BLADDER CANCER AND OTHER CANCERSMay 2021April 2024Allow3510NoNo
17334073CONJUGATED ANTIBODIES AGAINST LY75 FOR THE TREATMENT OF CANCERMay 2021June 2024Abandon3710NoNo
17308570Cancer Drug and UsesMay 2021June 2024Abandon3710NoNo
17241654METHODS FOR TREATING FIBROTIC CANCERSApril 2021June 2024Abandon3810NoNo
17283903DLL3 SINGLE DOMAIN ANTIBODIES AND THERAPEUTIC COMPOSITIONS THEREOFApril 2021March 2025Allow4720YesNo
17224722Methods for Manipulating Phagocytosis Mediated by CD47April 2021July 2024Allow4020NoNo
17205251COMPOSITIONS AND METHODS TO ENHANCE THE IMMUNE SYSTEMMarch 2021April 2024Allow3710NoNo
17275528SUBSTITUTED BENZAZEPINE COMPOUNDS, CONJUGATES, AND USES THEREOFMarch 2021June 2025Abandon5101NoNo
17198103Compositions and Methods for Selective Phagocytosis of Human Cancer CellsMarch 2021May 2025Allow5020NoNo
17195072METHODS OF ISOLATING T CELLS HAVING ANTIGENIC SPECIFICITY FOR A CANCER-SPECIFIC MUTATIONMarch 2021April 2024Allow3810NoNo
17190792PREPARATIONS AND METHODS FOR TREATING A GD2 POSITIVE CANCERMarch 2021June 2022Allow1530YesNo
17189135Drug-Conjugates, Conjugation Methods, And Uses ThereofMarch 2021June 2024Allow3910NoNo
17181896ANTIBODY CONJUGATES COMPRISING TOLL-LIKE RECEPTOR AGONISTFebruary 2021June 2024Abandon3910NoNo
17270034ANTI-PD-L1 CANCER IMMUNOTHERAPY ANTIBODIESFebruary 2021April 2025Allow5030NoNo
17268387ANTI-TISSUE FACTOR ANTIBODY-DRUG CONJUGATES AND THEIR USE IN THE TREATMENT OF CANCERFebruary 2021December 2024Abandon4610NoNo
17169093CANCER ANTIGEN SPECIFIC CYTOTOXIC T CELLFebruary 2021January 2024Abandon3510NoNo
17163205CD80 VARIANT IMMUNOMODULATORY PROTEINS AND USES THEREOFJanuary 2021April 2021Allow300YesNo
17159798COMBINATIONS OF IRS/STAT3 DUAL MODULATORS AND ANTI-CANCER AGENTS FOR TREATING CANCERJanuary 2021September 2024Allow4330NoNo
17153711NAPI2B-TARGETED ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOFJanuary 2021June 2024Abandon4110NoNo
17151898BI-FUNCTIONAL ALLOSTERIC PROTEIN-DRUG MOLECULES FOR TARGETED THERAPYJanuary 2021December 2023Abandon3510NoNo
17149405BIASED IL2 MUTEINS METHODS AND COMPOSITIONSJanuary 2021May 2022Allow1630YesNo
17260205BISPECIFIC AFFINITY REAGENT AND RELATED METHODS FOR PRETARGETED RADIOIMMUNOTHERAPY AGAINST CD45+ CELLSJanuary 2021May 2025Abandon5220NoNo
17146070METHOD AND COMPOSITIONS FOR DETECTING AN ADENOMA-ADENOCARCINOMA TRANSITION IN CANCERJanuary 2021February 2024Allow3720NoNo
17141931CD123 Antibodies and Conjugates ThereofJanuary 2021December 2023Abandon3510NoNo
17129633YEAST-BRACHYURY IMMUNOTHERAPEUTIC COMPOSITIONSDecember 2020December 2023Allow3620NoNo
17128944TUMOR LYSATE LOADED PARTICLESDecember 2020December 2023Abandon3610NoNo
17253086BINDER/ACTIVE AGENT CONJUGATES DIRECTED AGAINST CXCR5, HAVING ENZYMATICALLY CLEAVABLE LINKERS AND IMPROVED ACTIVITY PROFILEDecember 2020April 2025Abandon5220NoNo
17251657CONJUGATEDecember 2020June 2025Abandon5411NoNo
17111982SELF-STABILIZING LINKER CONJUGATESDecember 2020October 2023Abandon3410NoNo
17058190STABLE FUSION PROTEIN FORMULATIONNovember 2020June 2025Allow5430NoNo
17057589PHTHALOCYANINE DYE CONJUGATE COMPOSITIONSNovember 2020April 2025Allow5230YesNo
16951722NEO-EPITOPE VACCINES AND METHODS OF TREATING CANCERNovember 2020September 2024Abandon4601NoNo
17088220TREATMENT OF OVARIAN CANCER IN PATIENTS WITH ASCITES USING A SPECIFIC BINDING AGENT OF HUMAN ANGIOPOIETIN-2 IN COMBINATION WITH A TAXANENovember 2020August 2023Allow3410NoNo
17077661AUTOIMMUNE ANTIGENS AND CANCEROctober 2020October 2023Abandon3510NoNo
17076677IMMUNE MODULATION WITH TLR9 AGONISTS FOR CANCER TREATMENTOctober 2020September 2021Allow1010NoNo
17046694COMPOSITIONS AND METHODS FOR TREATING NECROTIZING ENTEROCOLITISOctober 2020March 2025Abandon5311NoNo
17045380ANTIBODY FORMULATIONOctober 2020March 2024Allow4110NoNo
17032219CAMPTOTHECIN DERIVATIVESSeptember 2020September 2021Allow1211NoNo
17022560Patient Treatment Via Teratogenic Pharmaceutical CompoundsSeptember 2020February 2024Allow4120NoNo
17015290ANTI-HIV ANTIBODIESSeptember 2020January 2024Abandon4010NoNo
17006681PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATESAugust 2020October 2023Abandon3710NoNo
16975406NON-NATURAL AMATOXIN-TYPE ANTIBODY CONJUGATEAugust 2020November 2024Allow5120YesNo
16992232METHODS FOR DETECTION OF CIRCULATING TUMOR CELLS AND METHODS OF DIAGNOSIS OF CANCER IN A MAMMALIAN SUBJECTAugust 2020October 2023Abandon3810NoNo
16989654FUSION PROTEIN CONTAINING TRAIL AND IGG BINDING DOMAIN AND THE USES THEREOFAugust 2020January 2024Allow4120YesNo
16641281METHODS OF INACTIVATING VIRAL CONTAMINANTSAugust 2020November 2024Allow5720NoNo
16966442VACCINE COMPOSITION AND USES THEREOFJuly 2020January 2025Allow5420NoNo
16933845ANTIBODY-STING AGONIST CONJUGATES AND THEIR USE IN IMMUNOTHERAPYJuly 2020March 2021Allow820NoNo
16963185ANTI-TUMOR THERAPEUTIC AGENTS BASED ON B7H RECEPTOR LIGANDSJuly 2020January 2025Allow5430YesNo
16920880PREPARATIONS AND METHODS FOR TREATING A GD2 POSITIVE CANCERJuly 2020March 2021Allow810YesNo
16959867COMPOSITIONS AND METHODS FOR INHIBITION OF ALPHAVIRUS INFECTIONJuly 2020March 2025Allow5721YesNo
16959950SUBSTITUTED HALO-QUINOLINE DERIVATES FOR USE IN THE TREATMENT OF LYMPHOMAS AND LEUKEMIAJuly 2020February 2024Abandon4320NoNo
16919191Radiohalogenated Agents for in Situ Immune Modulated Cancer VaccinationJuly 2020June 2024Allow4720NoNo
16918520MEDICINE FOR TREATING CANCER AND METHOD FOR TREATING CANCERJuly 2020July 2023Allow3610NoNo
16918527COMBINED PREPARATIONS FOR THE TREATMENT OF CANCERJuly 2020September 2024Allow5130NoNo
16959644NEUTRALIZING ANTIBODIES TO EBOLA VIRUS GLYCOPROTEIN AND THEIR USEJuly 2020December 2023Allow4210YesNo
16959288CYTOTOXICITY-INDUCING THERAPEUTIC AGENTJune 2020October 2022Abandon2710NoNo
16959425NOVEL COMBINATION AND USE OF ANTIBODIESJune 2020February 2025Allow5630NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner CANELLA, KAREN A.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
7
Examiner Affirmed
5
(71.4%)
Examiner Reversed
2
(28.6%)
Reversal Percentile
43.0%
Lower than average

What This Means

With a 28.6% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
113
Allowed After Appeal Filing
20
(17.7%)
Not Allowed After Appeal Filing
93
(82.3%)
Filing Benefit Percentile
18.8%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 17.7% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner CANELLA, KAREN A - Prosecution Strategy Guide

Executive Summary

Examiner CANELLA, KAREN A works in Art Unit 1643 and has examined 1,245 patent applications in our dataset. With an allowance rate of 59.9%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 40 months.

Allowance Patterns

Examiner CANELLA, KAREN A's allowance rate of 59.9% places them in the 13% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by CANELLA, KAREN A receive 2.40 office actions before reaching final disposition. This places the examiner in the 82% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by CANELLA, KAREN A is 40 months. This places the examiner in the 7% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +34.7% benefit to allowance rate for applications examined by CANELLA, KAREN A. This interview benefit is in the 85% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 27.7% of applications are subsequently allowed. This success rate is in the 39% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 55.7% of cases where such amendments are filed. This entry rate is in the 78% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 50.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 40% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 89.9% of appeals filed. This is in the 80% percentile among all examiners. Of these withdrawals, 90.3% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.

Petition Practice

When applicants file petitions regarding this examiner's actions, 60.3% are granted (fully or in part). This grant rate is in the 77% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 8.2% of allowed cases (in the 94% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.3% of allowed cases (in the 46% percentile). This examiner issues Quayle actions less often than average. Allowances may come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Expect multiple rounds of prosecution: This examiner issues more office actions than average. Address potential issues proactively in your initial response and consider requesting an interview early in prosecution.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Consider after-final amendments: This examiner frequently enters after-final amendments. If you can clearly overcome rejections with claim amendments, file an after-final amendment before resorting to an RCE.
  • Appeal filing as negotiation tool: This examiner frequently reconsiders rejections during the appeal process. Filing a Notice of Appeal may prompt favorable reconsideration during the mandatory appeal conference.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.